2型糖尿病患者阿卡波糖或胰岛素类似物治疗前后血清chemerin、脂联素、CA199的变化

Changes of serum chemerin,adiponectin,CA199 levels among patients with type 2 diabetes treated by different therapies of acarbose or insulinoid

目的研究2型糖尿病患者接受阿卡波糖或胰岛素类似物不同方法治疗前后血清chemerin、脂联素、CA199水平的变化情况,探讨三者与糖脂代谢的关系。方法 2型糖尿病患者接受阿卡波糖(A组,n=30)、精蛋白锌重组赖脯胰岛素混合注射液(25R)(B组,n=30)及短期门冬胰岛素皮下泵强化治疗(CSⅡ)(C组,n=30)。记录患者临床资料,采用ELISA法检测患者治疗前后血清chemerin、脂联素、CA199水平并探讨其联系。结果①治疗后,各组患者空腹血糖(FBG)、餐后2 h血糖(PBG)及糖化血红蛋白(HbA1C)下降(P<0.01);②较治疗前,治疗后各组chemer-in、CA199降低,脂联素升高,差异有统计学意义(P<0.01);③治疗后脂联素升高水平及空腹血糖下降水平组间差异有统计学意义(P<0.01)。结论随着2型糖尿病患者血糖下降,CA199、chemerin水平降低,脂联素水平升高,该变化可能参与糖脂代谢过程。

Objective To observe the changes of serum chemerin, adiponectin, CA199 levels among patients with type 2 diabetes who treated by different therapies of acarbose or insulinoid, and to explore the relationship between chemerin, adiponectin, CA199 and glucose and lipid metabolism. Methods Type 2 diabetes patients received acarbose （group A, n = 30）, protamine zinc and insulin lispro mixed injection （25R） （group B, n = 30）, or short-term subcutaneous insulin aspart pump therapy （ group C, n = 30 ）. Clinical data were recorded. Serum chemerin, adiponectin, CA199 levels before and after treatment were measured by enzyme-linked immunosorbent assay （ELISA）. T Tests, single-factor analysis of variance, Pearson correlation analysis were used for date analysis. Results （1） After treatment, the FBG, PBG, HbAIC of the patients in each group decreased （P 〈 0. 01 ） ; （2） The serum chemerin, CA199 levels decreased after treatment, while the serum adiponectin level increased. The differences were significant（P 〈0. 01 ） ; （3） The changed levels of adiponectin and fasting plasma glucose in each group were significantly different （ P 〈 0.01 ）. Conclusion With the decrease of blood glucose level among pa- tients with type 2 diabetes, CA199, chemerin levels decrease and adiponectin level increases, which may be in- volved in glucose and lipid metabolism.